BR0115206A - Composições hidroliticamente instáveis - Google Patents

Composições hidroliticamente instáveis

Info

Publication number
BR0115206A
BR0115206A BR0115206-8A BR0115206A BR0115206A BR 0115206 A BR0115206 A BR 0115206A BR 0115206 A BR0115206 A BR 0115206A BR 0115206 A BR0115206 A BR 0115206A
Authority
BR
Brazil
Prior art keywords
layer
hydrolytically unstable
unstable compositions
compositions
hydrophobic excipients
Prior art date
Application number
BR0115206-8A
Other languages
English (en)
Inventor
Debra Alida Odinik
I-Lan Sue
Gary Conard Visor
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0115206A publication Critical patent/BR0115206A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)

Abstract

"COMPOSIçõES HIDROLITICAMENTE INSTáVEIS". A presente invenção refere-se a uma nova formulação farmacêutica oral compreendendo: a) um núcleo formado pela parte central; b) uma primeira camada que inclui um revestimento de polímero selando o núcleo e opcionalmente um ou mais excipientes hidrofóbicos; e c) uma segunda camada revestindo a primeira camada, em que a segunda camada contém um ou mais compostos farmaceuticamente ativos instáveis em um ou mais excipientes hidrofóbicos aceitáveis.
BR0115206-8A 2000-11-10 2001-11-02 Composições hidroliticamente instáveis BR0115206A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24725700P 2000-11-10 2000-11-10
US32627401P 2001-10-01 2001-10-01
PCT/EP2001/012714 WO2002038133A2 (en) 2000-11-10 2001-11-02 Compositions containing hydrolytically unstable compounds

Publications (1)

Publication Number Publication Date
BR0115206A true BR0115206A (pt) 2003-10-07

Family

ID=26938563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115206-8A BR0115206A (pt) 2000-11-10 2001-11-02 Composições hidroliticamente instáveis

Country Status (12)

Country Link
US (1) US20020086057A1 (pt)
EP (1) EP1341529A2 (pt)
JP (1) JP2004520275A (pt)
KR (1) KR20030051794A (pt)
CN (1) CN1474686A (pt)
AR (1) AR037134A1 (pt)
AU (1) AU2002219071A1 (pt)
BR (1) BR0115206A (pt)
CA (1) CA2425594A1 (pt)
MX (1) MXPA03004040A (pt)
PE (1) PE20020586A1 (pt)
WO (1) WO2002038133A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040313A1 (it) * 2004-02-24 2004-05-24 S I I T S R L Servizio Interna Formulazioni gastroprotette di inbitori di enzimi ad attivita' alfa-amilasica
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
US9078830B2 (en) 2009-07-31 2015-07-14 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
JP2013523757A (ja) 2010-03-31 2013-06-17 スパーナス ファーマシューティカルズ インコーポレイテッド マジンドールの製剤
AU2017230974B2 (en) 2016-03-09 2022-02-03 Nls-1 Pharma Ag A mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
US5879920A (en) * 1991-10-07 1999-03-09 Genencor International, Inc. Coated enzyme-containing granule
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
JPH08333238A (ja) * 1995-06-02 1996-12-17 Shin Etsu Chem Co Ltd 液体状ワックスを用いる無溶媒腸溶性コーティング剤で被覆した腸溶性製剤
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції

Also Published As

Publication number Publication date
JP2004520275A (ja) 2004-07-08
CN1474686A (zh) 2004-02-11
AU2002219071A1 (en) 2002-05-21
KR20030051794A (ko) 2003-06-25
EP1341529A2 (en) 2003-09-10
AR037134A1 (es) 2004-10-27
MXPA03004040A (es) 2003-08-19
WO2002038133A2 (en) 2002-05-16
PE20020586A1 (es) 2002-07-06
CA2425594A1 (en) 2002-05-16
US20020086057A1 (en) 2002-07-04
WO2002038133A3 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
CA2338680A1 (en) Medicinal aerosol formulations
CA2315261A1 (en) Oral pharmaceutical extended release dosage form
JO2555B1 (en) Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent
BR0212475A (pt) Composições farmacêuticas
BR0212921A (pt) Composição farmacêutica com base em fondant
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
BR0015188A (pt) Composições farmacêuticas
BR0215262A (pt) Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
CA2207835A1 (fr) Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
ATE222748T1 (de) Orale zusammensetzung mit verbesserter aufnahme
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
SE9700885D0 (sv) New pharmaceutical formulation
BR0211198A (pt) Composições farmacêuticas e seu uso
BR0111868A (pt) Composições farmacêuticas
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
BR9913135A (pt) Formulação oral
ES2185452A1 (es) Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
BR0115206A (pt) Composições hidroliticamente instáveis
BE2016C017I2 (pt)
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
GEP20043377B (en) Pharmaceutical Complex
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
BR0213463A (pt) Composições farmacêuticas contendo macrólidos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.